Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | LIPE | Q05469 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 2/20 | 0.35 |
| ▸ | DRD5 | P21918 | 2/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3024960 | 1.00 | RORC (0.43) | RORCLIPETACR1PDE4BKDM4E | |
| SCHEMBL3032654 | 0.93 | RORC (0.42) | RORCLIPETACR1PDE4BKDM4E | |
| SCHEMBL3032651 | 0.93 | RORC (0.42) | RORCLIPETACR1PDE4BKDM4E | |
| SCHEMBL3655498 | 0.88 | HSD11B1 (0.37) | HSD11B1DRD2DRD1DRD4DRD5 | |
| SCHEMBL3019742 | 0.83 | DRD2 (0.46) | RORCLIPETACR1PDE4BKDM4E | |
| SCHEMBL3019743 | 0.83 | DRD2 (0.46) | RORCLIPETACR1PDE4BKDM4E | |
| SCHEMBL3023895 | 0.83 | DRD2 (0.46) | RORCLIPETACR1PDE4BKDM4E | |
| SCHEMBL3020609 | 0.82 | ESR2 (0.48) | RORCTACR1PDE4BKDM4ENAMPT | |
| SCHEMBL3020607 | 0.82 | ESR2 (0.48) | RORCTACR1PDE4BKDM4ENAMPT | |
| SCHEMBL3027212 | 0.82 | GHSR (0.47) | RORCTACR1PDE4BGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | N.V. ORGANON | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210680-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES | TPH1, HTR2C, TPH2 | RORC 1536/4885LIPE 288/4885TACR1 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.